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The objective of this study was to investigate an apparent increase in linezolid-nonsusceptible staphylococci and enterococci
following a laboratory change in antimicrobial susceptibility testing from disk diffusion to an automated susceptibility testing
system. Isolates with nonsusceptible results (n 27) from Vitek2 were subjected to a battery of confirmatory testing which in-
cluded disk diffusion, Microscan broth microdilution, Clinical and Laboratory Standards Institute (CLSI) reference broth mi-
crodilution, gradient diffusion (Etest), 23S rRNA gene sequencing, and cfr PCR. Our results show that there is poor correlation
betweenmethods and that only 70 to 75% of isolates were confirmed as linezolid resistant with alternative phenotypic testing
methods (disk diffusion, Microscan broth microdilution, CLSI broth microdilution, and Etest). 23S rRNA gene sequencing iden-
tified mutations previously associated with linezolid resistance in 16 (59.3%) isolates, and the cfr gene was detected in 3 (11.1%)
isolates. Mutations located at positions 2576 and 2534 of the 23S rRNA gene were most common. In addition, two previously
undescribed variants (at positions 2083 and 2345 of the 23S rRNA gene) were also identified andmay contribute to linezolid
resistance.
Linezolid is a synthetic oxazolidinone antibiotic that inhibitsbacterial protein synthesis by blocking the first step in ribo-
some assembly (1). This mechanism of action is unique to the oxa-
zolidinone class of antibiotics, and thus cross-resistance from other
antibiotics with protein synthesis targets is unlikely. The spectrumof
activity of linezolid includesmostGram-positive organisms andmy-
cobacteria but not Gram-negative organisms. Since its introduction
for clinical use in 2000, linezolid has remained nearly uniformly
active against all Gram-positive pathogens, includingmethicillin-re-
sistant Staphylococcus aureus (MRSA) and vancomycin-resistant
Enterococcus (VRE), and has been an important therapeutic agent
for treating infections with these multidrug-resistant organisms
(2). Recent data from global surveillance programs suggest that
99% of staphylococci (includingMRSA and coagulase-negative
staphylococci [CoNS]) and enterococci (including VRE) are sus-
ceptible to linezolid (2, 3).However, nonsusceptibility rates can be
higher within individual medical centers and when resistant
clones disseminate within a specific geographic area or health care
institution (4).
Antimicrobial susceptibility testing results are important in the
process of deciding whether to use linezolid as therapeutic agent,
especially when using linezolid to treat infections due to multi-
drug-resistant organisms. There are several potential mechanisms
that can mediate linezolid resistance. The most common mecha-
nism of resistance ismutation of the 23S rRNA subunit, leading to
alteration of the peptidyltransferase center (PTC) where con-
served residues interact directly with linezolid (5). Gram-positive
organisms possess multiple 23S rRNA alleles (4 to 6 copies), and
development of clinically significant resistance requires that more
than one allele be mutated (6). This likely explains the low fre-
quency of linezolid resistance.
Mutation of linezolid binding sites is themost commonmech-
anisms of resistance; however, acquired resistance mechanisms
have now been described (7). One example of nonmutational re-
sistance is acquisition of the natural cfr (chloramphenicol-flo-
rfenicol resistance) gene, which is a plasmid-carried gene encod-
ing a protein which catalyzes the posttranscriptional methylation
of the C-8 atom of a key residue (A2503) in the 23S rRNA (8). cfr
is a highly mobile genetic element that facilitates interspecies
spread, and to date, cfr has been identified in staphylococci (both
S. aureus and CoNS), enterococci, streptococci, and other, less
common Gram-positive pathogens (5). The result of methylation
by the cfr product is a multidrug resistance phenotype that in-
cludes linezolid, lincosamides, and streptogramins (9).
Given the critical nature of infections that are treated with
linezolid, it is imperative that laboratory methods accurately de-
tect resistance. The objective of this study was to investigate an
apparent increase in linezolid-nonsusceptible staphylococci and
enterococci following a laboratory change in antimicrobial sus-
ceptibility testing from disk diffusion to an automated suscepti-
bility testing system.
MATERIALS AND METHODS
Bacterial strains. Isolates were recovered from clinical specimens at
Barnes-Jewish Hospital (St. Louis, MO) as part of routine clinical care
from April to November 2012. The inclusion criterion was any Gram-
positive isolate testing intermediate or resistant to linezolid using the Vi-
tek2 system.
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Antimicrobial susceptibility testing. An initial finding of linezolid
nonsusceptibility on the Vitek2 was confirmed with repeat testing. Kirby-
Bauer disk diffusion using a 30-g disk (Becton, Dickinson and Com-
pany) was performed on Mueller-Hinton agar (Thermofisher, Lenexa,
KS); testing was performed and interpreted according to CLSI standards
(10). Per CLSI recommendations, linezolid zone sizes for staphylococci
were interpreted using transmitted light, and isolates were evaluated for
visible growth detected with the unaided eye. Isolates with any discernible
growth located inside the zone were classified as resistant. Gradient diffu-
sion testing using Etest (bioMérieux, Durham, NC) on Mueller-Hinton
agar (Thermofisher) was performed and interpreted according to the
manufacturer’s recommendations, and thus the Etest was read at 90%
inhibition. Testing with the Vitek2 GP70 card and Microscan positive
MIC panel PM29 was performed according to themanufacturers’ recom-
mendations. The PM29 was inoculated using the Prompt method and
interpreted visually. If trailing endpoints were observed on the PM29, the
MIC was interpreted as the first well in which trailing was observed. It
should be noted that bioMérieux lists linezolid as a card limitation for the
testing of Enterococcus species isolates. For disk diffusion, gradient diffu-
sion, and Microscan testing, quality control was conducted each day that
testing was performed; for Vitek2 analysis, quality control was performed
weekly.
At the Centers for Disease Control and Prevention (CDC), 96-well
MIC trays were prepared using 100l of cation-adjustedMueller-Hinton
broth (CAMHB) (BBL, Sparks, MD) per well; trays were kept frozen at
70°C and then thawed when ready for use. The linezolid broth microdi-
lution (BMD) testing range was 1 to 16 g/ml. BMD MIC testing was
performed by CLSI standardmethods (11, 12). A sterile 95-pin inoculator
and reservoir combination system (Evergreen Scientific, Los Angeles, CA)
was used to deliver 10 l of inoculum per well. Quality control was per-
formed with Enterococcus faecalis ATCC 29212 and Staphylococcus aureus
ATCC 29213 on the MIC panels containing linezolid; results were in ac-
ceptable ranges.
23S rRNA gene sequencing. Bacterial DNA was extracted from iso-
lated colonies or broth using 30l of the PrepManUltra reagent (Applied
Biosystems). Extraction supernatant (1 l) was used directly for PCR
amplification using the Easy-A PCR enzyme (Stratagene) and then se-
quenced bidirectionally using the samePCRprimers on the 3130xl genetic
analyzer (Life Technologies, Foster City, CA, USA). The PCR primers
(forward, 5=-AACGATTTGGGCACTGTCTCAACG-3=; reverse, 5=-AAT
TTCCTACGCCCACGACGGATA-3=) were designed for targeted ampli-
fication of a 660-bp region of the 23S rRNA gene domain V that is highly
conserved between Staphylococcus spp. and Enterococcus spp. This tar-
geted region includes the well-characterized linezolid resistance muta-
tions G2576T, T2500A, and G2234A.
Variants in the 23S rRNA gene were determined by comparing the
generated sequence to the reference sequence from GenBank (accession
number X68425). Heterozygous sequencing chromatogram peaks were
confirmed in the corresponding nucleotide position in the complemen-
tary sequence reaction.
cfr PCR. PCR for detection of cfr was performed using a modification
of a previously published method (13). In brief, DNA was extracted from
bacterial isolates grown on sheep blood agar (Remel) using the BiOstic
bacteremiaDNA isolation kit (MoBio, Carlsbad, CA). Approximately 100
ng of DNAwas subjected to PCR using primers cfr-fw (5=-TGAAGTATA
AAGCAGGTTGGGAG) and cfr-rev (5=-ACCATATAATTGACCACA
AGC AGC) and a PuReTaq Ready-To-Go PCR bead (GE Healthcare,
Buckinghamshire, United Kingdom) (13). PCR cycling conditions were
as follows: 94°C for 10 min; 35 cycles of 94°C for 30 s, 57°C for 30 s, and
74°C for 30 s; and a final elongation step at 72°C for 10min. Products were
visualized using agarose gel electrophoresis. Quality control was per-
formed with each PCR run; S. aureus ATCC 25923 was used as a negative
control, and S. aureus 004-737X 2007 was used as a positive cfr control
strain (this strain was kindly provided by JMI Laboratories).
Data analysis. Because intermethod correlation was poor, two gold
standards were used in this study to assess the performance of each
method. Gold standard 1 (GS1) was defined as any molecular result (23S
rRNA gene sequencing or cfr PCR) that identified an established resis-
tance determinant and/or yielded 100% concordance between pheno-
typic test results. Gold standard 2 (GS2) was determined by reference
broth microdilution, which was performed by the CDC.
RESULTS
Isolates. Twenty-seven isolates (11 Enterococcus [71% vancomy-
cin resistant], eight S. aureus [88%methicillin resistant], and eight
S. epidermidis [100% methicillin resistant]) were categorized as
either intermediate or resistant to linezolid by Vitek2 (Table 1).
All isolates were recovered from clinical specimens, including
blood (n  10), urine (n  5), cystic fibrosis sputum (n  5),
abscess (n 2), wound (n 1), thoracentesis fluid (n 1), bone
marrow (n  1), bone (n  1), and otherwise undefined biopsy
(n 1) specimens (Table 1). In total, 23 isolates tested as resistant
by Vitek2 with MICs of 8 g/ml, and 4 enterococcal isolates
tested as intermediate with MICs of 4 g/ml.
23S rRNA gene sequencing. To interrogate for mutations in
the 23S rRNA gene that can confer resistance to linezolid, the 23S
rRNA gene was sequenced. Of the 27 isolates, 16 (59%) had mu-
tations that have been previously reported to confer linezolid re-
sistance. Mutations which have not been previously associated
with linezolid resistance were identified in 9 (33%) of the isolates.
Consistent with previous literature, the most common mutation
identified was a guanine-to-thymidine transition at nucleotide
2576 (n  10). The G2576T mutation was identified most com-
monly in the enterococci (n  7) but was also seen in S. aureus
(n 1) and S. epidermidis (n 2) (Table 1). Additionalmutations
previously associated with linezolid resistance were also identified
but at a lower frequency, including T2500A (S. aureus [n  1]),
C2192A (S. aureus [n 1]), and C2534T (S. epidermidis [n 4]).
Interestingly, several previously undescribed variants were also
detected (Table 2). The combination of ambiguous phenotypic
profiles and overlapping mechanisms of resistance makes it diffi-
cult to establish the significance of some of these novel variants.
However, our data suggest that G2083T, which was identified in
two S. aureus isolates, and G2345A, which was identified from a
single S. epidermidis isolate, may be the sole cause of linezolid
resistance in those isolates. Both of these variants were present in
isolates with no other identified mechanisms of resistance and
with phenotypic resistance profiles consistent with linezolid resis-
tance. Lastly, 6 isolates had no identified 23S rRNA gene variants.
Assessment of cfr. Three isolates were positive for cfr by PCR.
One isolate of Enterococcus faecalis was cfr positive and had no
mutation in the 23S rRNAgene. This isolate tested as intermediate
(MIC 4g/ml) by theVitek2 and brothmicrodilution, resistant
by Etest (MIC 8 g/ml) and disk diffusion (zone diameter 6
mm), and susceptible by Microscan broth microdilution (MIC
2 g/ml). This is in contrast to the case for the S. aureus and S.
epidermidis isolates containing cfr; these isolates were resistant to
linezolid by all testingmethods employed. However, these isolates
also possessed variants in the 23S rRNA gene, and it may be that
the combination of the two concomitantmechanisms contributed
to a more resistant phenotype.
Antimicrobial susceptibility testing. Etest, disk diffusion,
broth microdilution, and Microscan broth microdilution re-
sults confirmed reduced susceptibility in 19 (70%), 21 (78%),
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20 (75%), and 20 (75%) of isolates tested, respectively (Table
1). In an effort to evaluate the accuracy of Vitek2, Etest, disk
diffusion, and Microscan broth microdilution detection of re-
duced linezolid susceptibility, two gold standards were estab-
lished. The first gold standard (GS1) defined linezolid resis-
tance as an isolate with a positive molecular assay for linezolid
resistance (that is, a previously described 23S rRNA gene mu-
tation associated with linezolid resistance or presence of cfr) or
complete categorical agreement among phenotypic methods.
Using this strict gold standard, eight (30%), two (7.5%), two
(7.5%), and four (15%) of Vitek2, Etest, disk diffusion, and
Microscan broth microdilution results were falsely resistant,
respectively. Similarly, Etest, disk diffusion, and Microscan
broth microdilution each generated falsely susceptible results
for two (7.4%), two (7.4%), and three (11%) isolates, respec-
tively. Of note, these methods did not correlate well, and the
isolates that were falsely classified as susceptible differed be-
tween methods.
A second gold standard (GS2) defined linezolid resistance
according to reference broth microdilution testing performed
by the CDC. By this measure, 5 (19%), one (3.7%), two (7.4%),
and one (3.7%) of Vitek2, Etest, disk diffusion, and Microscan
broth microdilution results were falsely resistant, respectively.
In addition, Etest and disk diffusion each generated falsely sus-
ceptible results for three (11%) isolates, while Microscan broth
microdilution generated two (7.4%) falsely susceptible results.
As a result of the fact that these isolates were selected on the
basis of linezolid nonsusceptibility using Vitek2, the analytical

























E. faecalis Urine 4 (I) 2 (S) 25 (S) 2 (S) 2 (S) None Neg S S
Pelvic abscess 4 (I) 2 (S) 21 (I) 2 (S) 2 (S) None Neg S S
Urine 8 (R) 16 (R) 19 (R) 4 (I/R) 16 (R) 2576 G¡T Neg R R
Blood 4 (I) 8 (R) 6 (R) 2 (S) 4 (I) None Pos R I
Urine 4 (I) 4 (I) 25 (S) 4 (I) 2 (S) None Neg S S
E. faecium Blood 8 (R) 8 (R) 19 (R) 4 (I/R) 16 (R) 2576 G¡T Neg R R
Urine 8 (R) 2 (S) 18 (R) 2 (S) 4 (I) 2576 G¡T Neg R I
Blood 8 (R) 16 (R) 14 (R) 4 (I/R) 16 (R) 2576 G¡T Neg R R
Blood 8 (R) 64 (R) 8 (R) 4 (I/R) 16 (R) 2576 G¡T Neg R R
Thoracentesis fluid 8 (R) 64 (R) 15 (R) 4 (I/R) 16 (R) 2576 G¡T Neg R R
Biopsy specimen 8 (R) 8 (R) 15 (R) 4 (I/R) 16 (R) 2576 G¡T Neg R R
S. aureus CF sputum 8 (R) 64 (R) 13 (R) 4 (R) 16 (R) 2234 G¡A, 2326 T¡C,
2500 T¡A
Neg R R
Abdominal abscess 8 (R) 2 (S) 27 (S) 4 (S) 2 (S) None Neg S S
Toe wound 8 (R) 16 (R) 20 (R) 4 (R) 16 (R) 2083 G¡T Pos R R
CF sputum 8 (R) 4 (S) 22 (I) 4 (R) 8 (R) 2083 G¡T Neg S R
CF sputum 8 (R) 4 (S) 24 (S) 4 (R) 8 (R) 2083 G¡T Neg S R
CF sputum 8 (R) 4 (S) 27 (S) 4 (S) 4 (S) 2058 A¡G, 2059 A¡G Neg S S
CF sputum 8 (R) 8 (R) 23 (S) 4 (R) 16 (R) 2234 G¡A, 2576 G¡T Neg R R
Urine 8 (R) 4 (S) 6 (R) 4 (S) 4 (S) 2192 C¡A, 2207 C¡A,
2341 G¡A
Neg R S
S. epidermidis Bone 8 (R) 256 (R) 6 (R) 4 (R) 16 (R) 2534 C¡T Pos R R
Bone marrow 8 (R) 64 (R) 6 (R) 4 (R) 16 (R) 2576 G¡T Neg R R
Blood 8 (R) 32 (R) 14 (R) 4 (R) 16 (R) 2534 C¡T Neg R R
Blood 8 (R) 16 (R) 26 (S) 4 (R) 16 (R) None Neg S R
Blood 8 (R) 8 (R) 22 (I) 4 (R) 8 (R) 2345 G¡A Neg R R
Blood 8 (R) 256 (R) 6 (R) 4 (R) 16 (R) 2576 G¡T Neg R R
Blood 8 (R) 32 (R) 15 (R) 4 (R) 16 (R) 2219 T¡C, 2534 C¡T Neg R R
Blood 8 (R) 32 (R) 16 (R) 4 (R) 16 (R) 2534 C¡T Neg R R
a Shading indicates an error with either gold standard 1 (GS1) or gold standard 2 (GS2). GS1 is defined by a positive result for a molecular marker of linezolid resistance and/or complete
agreement amongst phenotypic tests. GS2 is defined by the CLSI brothmicrodilution result. CF, cystic fibrosis; R, resistant; I, intermediate; S, susceptible; Neg, negative; Pos, positive.
b Bold indicates a mutation of known significance.
TABLE 2 Characterization of 23S rRNA variants detected in this study









2083 G¡T No S. aureus 16 (R) 16 (R) Yes
2083 G¡T No S. aureus 8 (R) 4 (S) No
2083 G¡T No S. aureus 8 (R) 4 (S) No
2234 G¡A Yes S. aureus 16 (R) 8 (R) No
2326 T¡C Yes S. aureus 16 (R) 64 (R) No
2058 A¡G No S. aureus 4 (S) 4 (S) No
2059 A¡G No S. aureus 4 (S) 4 (S) No
2234 G¡A Yes S. aureus 16 (R) 64 (R) No
2207 C¡A Yes S. aureus 4 (S) 4 (S) No
2341 G¡A Yes S. aureus 4 (S) 4 (S) No
2345 G¡A No S. epidermidis 8 (R) 8 (R) No
2219 T¡C Yes S. epidermidis 16 (R) 32 (R) No
a Shading indicates reduced susceptibility. BMD, broth microdilution; R, resistant; S,
susceptible.
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performance characteristics of that method cannot be accu-
rately characterized.
Regardless of the organism being tested, these data show that
there is poor correlation between susceptibility testing methods
when it comes to detecting linezolid resistance. This is a significant
finding, as current CLSI standards suggest that laboratories
should confirm reduced linezolid susceptibility in staphylococci
and enterococci using a second method (14). Of the 27 isolates
included in this study, only 14 (51.9%) produced concordant re-
sults across all methods (Vitek2, Etest, disk diffusion, Microscan
broth microdilution, CDC broth microdilution, and molecular
[23S rRNA gene and cfr PCR considered together]), suggesting
that confirmatory methods readily available to clinical laborato-
ries are likely to produce conflicting results. Most laboratories do
not have access to themolecular methods used in this study and
must therefore rely on phenotypic confirmatory methods. If
molecular methods are excluded, only 15 (55.6%) of the 27
isolates produced concordant results for all phenotypic meth-
ods (Table 1).
DISCUSSION
This is one of the first studies to perform a systematic compar-
ison of susceptibility testing methods for the detection of lin-
ezolid resistance. However, Qi et al. did evaluate the ability of
Etest, agar dilution, broth microdilution, disk diffusion, and
Vitek2 to detect decreased linezolid susceptibility in entero-
cocci with G2576Tmutations (15). The purpose of the study by
Qi et al. was to assess the impact of G2576T mutation on phe-
notypic susceptibility. Despite testing a relatively small sample
size of linezolid-resistant isolates and only two species of En-
terococcus (E. faecium [n 14] and E. faecalis [n 5]), the authors
were able to conclude that for enterococci with the G2576T mu-
tation, the gradient diffusionmethodwas the least reliablemethod
and overcalled resistance more than any other method. One lim-
itation of the study by Qi et al. is that it was conducted between
2004 and 2005, and the only mutation they assessed was the
G2576T mutation. Since that time, numerous other variants,
some of which have been described in our study, have been iden-
tified, in addition to the emergence of cfr-mediated resistance. In
addition, our investigation includes Staphylococcus spp., which
were not tested in the study by Qi et al.
In another investigation, Tenover et al. evaluated enterococci
(n  50) and staphylococci (n  50), of which 17 and 15 were
nonsusceptible, respectively. They compared seven methods, the
Vitek, Vitek2,MicroscanWalkAway, BD Phoenix (BDDiagnostic
Systems, Sparks, MD), Etest, disk diffusion, and broth microdilu-
tion (16). As in our study, they found that there was poor categor-
ical agreement betweenmethods.When testing linezolid-nonsus-
ceptible staphylococci with Etest, disk diffusion, Vitek2, and
Microscan, very major errors were generated for 40%, 53.3%,
6.7%, and 6.7% of isolates, respectively. Performance was better
with enterococci, but verymajor errors were still generated for 6%
(Etest), 4% (disk diffusion), 10% (Vitek2), and 6% (Microscan) of
isolates.
Our findings illustrate the difficulty in establishing breakpoints
for antibiotics towhich resistance is rare. In addition, the issue can
be exacerbated and categorical interpretation can be a challenge
when the wild-type MIC distribution hovers around or ap-
proaches that of the susceptible/resistant breakpoint, as is the case
for linezolid and the staphylococci and enterococci (2). Further, in
the absence of an intermediate category (staphylococci), it is pos-
sible that the allowable error for any susceptibly testing method
(i.e., plus or minus one doubling dilution) contributed to the lack
of category agreement observed in some instances in our investi-
gation.
Linezolid is a bacteriostatic antibiotic and as such can generate
susceptibility patterns that can be challenging to interpret (16, 17).
Etest, for example, requires that 90% inhibition be considered
when determining the MIC, while disk diffusion requires the use
of transmitted light. In both cases there is some subjectivity in
reading zone sizes, which may lead to poor test correlation as
demonstrated here and by others (16). Broth microdilution also
poses some interpretive difficulty, as trailing endpoints can be
encountered andmay explainMICvariation between studies (17).
Our study identified several previously unreported 23S rRNA
gene variants in linezolid-resistant isolates which may represent
novel linezolid resistance determinants. The linezolid binding site
is surrounded by eight 23S rRNA gene nucleotides (18). Resis-
tance to linezolid has primarily been characterized by mutations
found in close proximity to the peptidyltransferase center (PTC).
However, it has been postulated that binding specificity may be
determined by nucleotides that are distal to the primary binding
site (18). Assessment of the protein structure published byWilson
et al. suggests that several of the variants identified in our study are
in close proximity to the linezolid binding site and could possibly
lead to resistance (19). Nucleotides 2061 and 2062 lie at the heart
of the linezolid binding site and have been shown to confer resis-
tance. The variant A2058G, A2059G, and G2083T mutations are
close to nucleotides 2061 and 2062. In addition, nucleotide 2058
has been shown to confer linezolid resistance in Mycobacterium
smegmatis, which strongly suggests that itmay have the same effect
in Gram-positive bacteria. Unfortunately, our phenotypic results
were ambiguous for the isolate harboring 2058 and 2059 variants,
and we cannot make a definitive conclusion about their signifi-
cance.
Two isolates harboring a variant at nucleotide 2083 demon-
strated phenotypic resistance and were cfr PCR negative. Interest-
ingly, these isolates were phenotypically resistant when tested by
broth microdilution and Vitek2 but were susceptible by gradient
diffusion. One of the two isolates demonstrated intermediate re-
sistance by disk diffusion. Despite the lack of agreement between
phenotypic results for isolates harboring a variant at nucleotide
2083, these isolates are clearly not exhibiting wild-type suscepti-
bility to linezolid. However, the 2083 variant was also found in a
third isolate thatwas cfrpositive, and therefore, at this time, it does
remain a variant of unknown significance.
Lastly, a single isolate of S. epidermidis was cfr negative and
found to harbor a 23S rRNA gene variant at nucleotide 2345. This
isolate was linezolid nonsusceptible by all phenotypic methods.
Interestingly, the location of this variant is distal to the linezolid
binding pocket, so the mechanism by which it confers resistance
remains to be determined.
This study has several limitations. First, all isolates were se-
lected for inclusion in this study by testing intermediate or resis-
tant to linezolid on the Vitek2. This selection bias does not permit
anymeaningful conclusions regarding the rate at which theVitek2
generates falsely resistant or susceptible results. Establishing a false
susceptibility rate for Vitek2 would have required screening for
linezolid resistance using another method, which was outside the
scope of this study. Second, the genes encoding the L3 and L4
Doern et al.
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ribosomal proteins were not sequenced. Mutations in these pro-
teins have only recently been described, and their association with
resistance is less certain than that of mutations found in the 23S
rRNA gene. Initially, in vitro studies suggested that these muta-
tions conferred reduced susceptibility to linezolid (20). Since that
time, though, few studies have confirmed the association between
thesemutations and linezolid resistance,making this only aminor
limitation of our study. Third, this study was based on isolates
yielding reduced susceptibility when tested with the Vitek2. Given
that linezolid testing for enterococci is listed as a card limitation
on the Vitek2, it is not surprising that resistance was not always
confirmed in these isolates. Lastly, because reduced susceptibility
to linezolid is a rare occurrence, this study is limited by small
numbers of isolates representing each species.
Here we demonstrate poor intermethod correlation for lin-
ezolid susceptibility testing; this result raises the question of how
laboratories should confirm linezolid resistance. Laboratories are
likely to encounter discrepant results with different methods for
testing linezolid. Our data suggest that Etest and disk diffusion
were the least likely to generate falsely resistant results and may
therefore represent specific confirmatory methods. However,
both methods did yield falsely susceptible results (very major er-
rors), which is of concern and must be considered when deciding
how to handle discrepant confirmatory methods. Emerging mo-
lecular biomarkers of resistance such as cfr and the 23S rRNA gene
are promising, but as demonstrated by this study, they cannot be
used in isolation and furthermore are not readily available for
many clinical laboratories.
There are multiple mechanisms that can confer linezolid resis-
tance in Gram-positive bacteria, and the MICs associated with
resistance can be variable, depending on species and genotype.
Laboratories should be aware that overall, linezolid resistance is an
uncommon finding, and confirmatory testing should be per-
formed when resistance is identified.
In conclusion, we agree that laboratories should continue to
follow the confirmatory algorithm outlined in appendix A of the
CLSI M100-S25 document (11). While following CLSI guidance,
laboratories should be reminded that reading endpoints for lin-
ezolid susceptibility testing can be challenging and that testing is
best performed by experienced laboratory personnel. These data
suggest that Etest and disk diffusion demonstrate sufficiently high
specificity for resistance and are therefore acceptable for use in this
capacity. Reference broth microdilution is considered the gold
standard and is encouraged when possible; however, few labora-
tories have access to thismethod, necessitating that isolates be sent
to reference laboratories for confirmatory testing. The results
from23S rRNAgene and cfrPCRare usefulwhen they are positive;
however, when they are negative, the possibility of resistance is not
excluded. These data indicate that in the absence of broth mi-
crodilution, laboratories will fail to confirm resistance in a high
percentage of isolates. Given the significance of falsely reporting
an isolate as susceptible, many laboratories will elect to report the
isolate as resistant regardless of the confirmatory test result. How-
ever, this decision is one that should be made on a case-by-case
basis and in consultation with the laboratorymedical director and
infectious disease practitioners. Once decisions about how to han-
dle discrepant results are made, laboratories can standardize the
timing and manner in which these susceptibility results are com-
municated.
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